MR imaging and MIBG scintigraphy of pheochromocytomas and extraadrenal functioning paragangliomas.
To compare the potential of magnetic resonance (MR) imaging and scintigraphy performed with radiotracer-labeled metaiodobenzyl-guanidine (MIBG) in localization and characterization of functioning paragangliomas, the authors analyzed results of both modalities in 33 patients. Overall sensitivity for detection was 91% for MR imaging and 80% for MIBG scintigraphy. MR imaging demonstrated 100% of adrenal paragangliomas and 75% of extraadrenal paragangliomas, whereas MIBG scintigraphy revealed 75% and 88%, respectively. MIBG scintigraphy was more specific in the characterization of paragangliomas than MR imaging (100% vs 82%). However, MR imaging demonstrated nine other lesions not seen on scintigrams. On the basis of their results and other considerations, the authors believe MR imaging is the preferred initial technique when a functioning paraganglioma is suspected.
van Gils
A P
AP
Department of Diagnostic Radiology, Leiden University Hospital, The Netherlands.
Falke
T H
TH
van Erkel
A R
AR
Arndt
J W
JW
Sandler
M P
MP
van der Mey
A G
AG
Hoogma
R P
RP
D019797:3-Iodobenzylguanidine; D000310:Adrenal Gland Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging; D000328:Adult; D000368:Aged; D003287:Contrast Media; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007462:Iodobenzenes; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009377:Multiple Endocrine Neoplasia / Q000175:diagnosis / Q000000981:diagnostic imaging; D010236:Paraganglioma, Extra-Adrenal / Q000175:diagnosis* / Q000000981:diagnostic imaging; D010673:Pheochromocytoma / Q000175:diagnosis* / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
D003287:Contrast Media; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine